See Recent Shionogi-Sponsored Congress Presentations
Congresses
As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Select a congress event or filter to view available congress presentations.
You Are Viewing Presentations
Outcomes of patients treated with cefiderocol for infections caused by β-lactam–β-lactamase inhibitor non-susceptible bacteria: subgroup analysis of the PROVE study
Outcomes of patients treated with cefiderocol for infections caused by β-lactam–β-lactamase inhibitor non-susceptible bacteria: subgroup analysis of the PROVE study
Pharmacodynamic assessment of combination of cefiderocol with xeruborbactam in murine thigh infection model
Pharmacodynamic assessment of combination of cefiderocol with xeruborbactam in murine thigh infection model
Pharmacokinetics, safety, and tolerability of ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2, in participants with hepatic impairment
Pharmacokinetics, safety, and tolerability of ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2, in participants with hepatic impairment
Phenotyping and genotyping analysis using baseline swab samples in ensitrelvir clinical studies
Phenotyping and genotyping analysis using baseline swab samples in ensitrelvir clinical studies
Population pharmacokinetic/pharmacodynamic analysis of cefiderocol in Chinese patients with complicated urinary tract infections
Population pharmacokinetic/pharmacodynamic analysis of cefiderocol in Chinese patients with complicated urinary tract infections
Pre-exposure prophylactic treatment with ensitrelvir inhibited SARS-CoV-2 infection in hamster aerosol transmission model
Pre-exposure prophylactic treatment with ensitrelvir inhibited SARS-CoV-2 infection in hamster aerosol transmission model
You Are Viewing Congress Locations
ASCP 2025
NACFC 2025
IDWeek 2025
AVG and IMRP 2025
ASM Microbe 2025
ESCMID 2025
CROI 2025
SCCM 2025
IDWeek 2024
NACFC 2024
IAS 2024
ESCMID 2024
